Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).

[1]  F. Messerli,et al.  Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. , 2004, Journal of the American College of Cardiology.

[2]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[3]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[4]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[5]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[6]  M. Nieminen,et al.  Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.

[7]  C. Bregonzio,et al.  Protection Against Ischemia and Improvement of Cerebral Blood Flow in Genetically Hypertensive Rats by Chronic Pretreatment With an Angiotensin II AT1 Antagonist , 2002, Stroke.

[8]  T. Unger,et al.  The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers , 2002, Journal of Human Hypertension.

[9]  G. Mancia,et al.  Systolic blood pressure: an underestimated cardiovascular risk factor. , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[10]  W. Rascher,et al.  Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats , 2002, Journal of hypertension.

[11]  T. Tanigawa,et al.  The relation of anger expression with blood pressure levels and hypertension in rural and urban Japanese communities , 2002, Journal of hypertension.

[12]  Jan A Staessen,et al.  Cardiovascular protection and blood pressure reduction: a meta-analysis , 2001, The Lancet.

[13]  S S Franklin,et al.  Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives: Analysis Based on National Health and Nutrition Examination Survey (NHANES) III , 2001, Hypertension.

[14]  T. Hedner,et al.  Stroke is More Common than Myocardial Infarction in Hypertension: Analysis based on 11 Major Randomized Intervention Trials , 2001, Blood pressure.

[15]  J. Saavedra,et al.  Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. , 2000, Stroke.

[16]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[17]  A. Hofman,et al.  Study on COgnition and Prognosis in the Elderly (SCOPE). , 1999, Blood pressure.

[18]  T. Herdegen,et al.  Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. , 1999, Stroke.

[19]  P. Rosenstiel,et al.  The Angiotensin II Type 2 (AT2) Receptor Promotes Axonal Regeneration in the Optic Nerve of Adult Rats , 1998, The Journal of experimental medicine.

[20]  Y. Fujisawa,et al.  Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. , 1997, Clinical and experimental hypertension.

[21]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[22]  N. Cook,et al.  Implications of small reductions in diastolic blood pressure for primary prevention. , 1995, Archives of internal medicine.